Owners, management and financials
CVR: 39859173
Previous names: Ebumab ApS
DKK -5,463,240
Gross profit
Net result: DKK -7,576,022
Ebumab Holding ApS (100%)
CVR · view owners
Johan Henrik Faber
Board: Hans Heugh Wandall (chair) and 4 members
CVR · view management
Active
Founded 10 September 2018
CVR · view overview
2 employees
CVR · 2026
Director role ended: Anne Reker Cordt
CVR · 06/02/2026
View the full event history
Cymab ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ebumab ApS. The management consists of Johan Henrik Faber. The board consists of Hans Heugh Wandall (chair), Johan Henrik Faber, Mads Nikolaj Behrndt-Eriksen and Søren Erik Bjørn. The company is owned by Ebumab Holding ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK -5,463,240 and a net result of DKK -7,576,022 compared with DKK -4,627,624 the year before. Equity in the 2025 report amounted to DKK -20,227,476.
Selskabets formål er at drive virksomhed indenfor forskning, udvikling og markedsføring af farmaceutiske og medicinske præparater samt anden efter bestyrelsens skøn beslægtet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | - | -7.6 mio. | 5.8 mio. | -20.2 mio. | 3 | |
| 202401/01/2024 – 31/12/2024 | - | -4.6 mio. | 12.6 mio. | -12.7 mio. | 3 | |
| 202301/01/2023 – 31/12/2023 | - | -2.6 mio. | 5.6 mio. | -8 mio. | 2 | |
| 202201/01/2022 – 31/12/2022 | 0 | -1.5 mio. | 5.2 mio. | -5.4 mio. | 2 | |
| 202101/01/2021 – 31/12/2021 | - | -943 t. | 383 t. | -3.9 mio. | 1 | |
| 202001/01/2020 – 31/12/2020 | 0 | -956 t. | 343 t. | -3 mio. | - |
Compared to 129 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationThe CVR number of Cymab ApS is 39859173.
Cymab ApS is owned by Ebumab Holding ApS.
The management of Cymab ApS consists of Johan Henrik Faber.
The board of Cymab ApS consists of Hans Heugh Wandall, Johan Henrik Faber and Mads Nikolaj Behrndt-Eriksen, with Hans Heugh Wandall as chair.
In 2025, Cymab ApS reported a gross profit of DKK -5,463,240.
Cymab ApS had 2 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Cymab ApS has published its annual report for 2025. Gross profit came to DKK -5,463,240, and the net result was DKK -7,576,022.
As of February 6, 2026, Anne Reker Cordt has left the board of directors of Cymab ApS.
As of February 6, 2026, Anne Reker Cordt has stepped down as director of Cymab ApS.
Cymab ApS has published its annual report for 2024. Gross profit came to DKK -1,951,697, and the net result was DKK -4,627,624.
As of February 25, 2025, Beierholm Godkendt Revisionspartnerselskab has been appointed auditor of Cymab ApS.
As of February 25, 2025, Slotsgade Revision ApS has stepped down as auditor of Cymab ApS.
Cymab ApS has published its annual report for 2023. Gross profit came to DKK -1,206,027, and the net result was DKK -2,580,789.
As of June 24, 2024, Anne Reker Cordt has joined the board of directors of Cymab ApS.
As of June 24, 2024, Anne Reker Cordt is registered as director of Cymab ApS.
As of May 31, 2024, Stine Louise Reedtz Kjellev has stepped down as director of Cymab ApS.
Cymab ApS has published its annual report for 2022. Revenue came to DKK 0, and the net result was DKK -1,541,246.
As of April 17, 2023, Hans Heugh Wandall has joined the board of directors of Cymab ApS.
As of April 17, 2023, Thomas Dal Stenfeldt Batchelor has joined the board of directors of Cymab ApS.
As of April 17, 2023, Mads Nikolaj Behrndt-Eriksen has joined the board of directors of Cymab ApS.
As of April 17, 2023, Johan Henrik Faber is registered as adm. dir. of Cymab ApS.
As of April 17, 2023, Stine Louise Reedtz Kjellev is registered as director of Cymab ApS.
As of April 17, 2023, Hans Heugh Wandall has stepped down as adm. dir. of Cymab ApS.
On April 17, 2023, the company changed its name from Ebumab ApS to Cymab ApS.
As of April 16, 2023, Hans Heugh Wandall has left the board of directors of Cymab ApS.
As of April 16, 2023, Thomas Dal Stenfeldt Batchelor has left the board of directors of Cymab ApS.
As of April 16, 2023, Johan Henrik Faber has stepped down as director of Cymab ApS.
Cymab ApS has published its annual report for 2021. Gross profit came to DKK -566,735, and the net result was DKK -942,533.
Cymab ApS has published its annual report for 2020. Revenue came to DKK 0, and the net result was DKK -955,753.
As of May 21, 2021, Hans Heugh Wandall has joined the board of directors of Cymab ApS.
As of May 21, 2021, Thomas Dal Stenfeldt Batchelor has joined the board of directors of Cymab ApS.
As of May 21, 2021, Hans Heugh Wandall is registered as adm. dir. of Cymab ApS.
As of May 20, 2021, Hans Heugh Wandall has left the board of directors of Cymab ApS.
As of May 20, 2021, Thomas Dal Stenfeldt Batchelor has left the board of directors of Cymab ApS.
Cymab ApS has published its interim report for the period September 10, 2018 to December 31, 2019.
As of July 15, 2020, Slotsgade Revision ApS has been appointed auditor of Cymab ApS.
As of July 15, 2020, KAPPELSKOV REVISION. GODKENDT REVISIONSAKTIESELSKAB has stepped down as auditor of Cymab ApS.
As of June 22, 2020, Hans Heugh Wandall has joined the board of directors of Cymab ApS.
As of June 22, 2020, Søren Erik Bjørn has joined the board of directors of Cymab ApS.
As of June 22, 2020, Kim Stengaard Holmsted has left the board of directors of Cymab ApS.
As of June 21, 2020, Hans Heugh Wandall has left the board of directors of Cymab ApS.
As of June 1, 2019, Johan Henrik Faber has joined the board of directors of Cymab ApS.
As of June 1, 2019, Thomas Dal Stenfeldt Batchelor has joined the board of directors of Cymab ApS.
As of June 1, 2019, Kurt Flemming Holmsted has left the board of directors of Cymab ApS.
As of June 1, 2019, Johan Henrik Faber is registered as director of Cymab ApS.
As of June 1, 2019, Kurt Flemming Holmsted has stepped down as director of Cymab ApS.
As of September 10, 2018, KAPPELSKOV REVISION. GODKENDT REVISIONSAKTIESELSKAB has been appointed auditor of Cymab ApS.
As of September 10, 2018, Kurt Flemming Holmsted has joined the board of directors of Cymab ApS.
As of September 10, 2018, Hans Heugh Wandall has joined the board of directors of Cymab ApS.
As of September 10, 2018, Kim Stengaard Holmsted has joined the board of directors of Cymab ApS.
As of September 10, 2018, Kurt Flemming Holmsted is registered as director of Cymab ApS.
As of September 10, 2018, Ebumab Holding ApS is registered as an owner of Cymab ApS with an ownership share of 100%.
Cymab ApS was founded on September 10, 2018.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Companies in the same industry and area
CVR 38402056
CVR 39880377
CVR 42057428
CVR 43432583
CVR 43575627
